Skip to main content
Year archive

BioInvent International — 2021 filings

All 49 regulatory filings released by BioInvent International (BINV) in 2021, sourced directly from the official regulator.

49 Filings
2021 Period
2021 filings (49)
Filing Released Lang
BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab
Regulatory Filings
2021-12-17 English
BioInvent presenterar positiva tidiga data från den pågående studien av BI-1206 i kombination med pembrolizumab för behandling av solida tumörer
Regulatory Filings
2021-12-17 Swedish
BioInvents senaste BI-1206 NHL-data som presenteras på ASH visar på ökat och varaktigt svar hos återfallspatienter
Earnings Release FY 2021
2021-12-11 Swedish
BioInvent’s latest NHL data at ASH show increased and sustained responses to BI-1206 in relapsed patients
Legal Proceedings Report
2021-12-11 English
BioInvent presenterar ytterligare positiva kliniska data för BI-1206 på ASH-konferensen i december 2021
Earnings Release FY 2021
2021-11-04 Swedish
BioInvent to show further positive BI-1206 clinical data in December at ASH 2021
Regulatory Filings
2021-11-04 English
Interim / Quarterly Report 2021
Interim / Quarterly Report 9M 2021
2021-10-28 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report 9M 2021
2021-10-28 English
Earnings Release 2021
Earnings Release H1 2021
2021-08-26 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report H1 2021
2021-08-26 English
BioInvent annonserar ett andra samarbets- och leveransavtal för att utvärdera BI-1808 i kombination med KEYTRUDA[® ](pembrolizumab) i patienter med avancerade solida tumörer
Regulatory Filings
2021-08-06 Swedish
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA[®] (pembrolizumab) in Patients with Advanced Solid Tumors
Regulatory Filings
2021-08-06 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-05-05 English
Beslut på BioInvents årsstämma 2021
AGM Information
2021-04-29 Swedish
Resolutions at BioInvent’s Annual General Meeting 2021
AGM Information
2021-04-29 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-04-28 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-04-28 English
Annual Report 2020
Annual Report FY 2020
2021-04-08 Swedish
Annual Report 2020
Annual Report FY 2020
2021-04-08 English
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2021-03-31 English
Ändring av antalet aktier och röster i BioInvent International AB
Share Issue/Capital Change
2021-03-31 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-30 English
NOTICE TO ANNUAL GENERAL MEETING IN BIOINVENT INTERNATIONAL AB
AGM Information
2021-03-29 English
KALLELSE TILL ÅRSSTÄMMA I BIOINVENT INTERNATIONAL AB
AGM Information
2021-03-29 Swedish
BioInvent publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm
Capital/Financing Update
2021-03-26 English
BioInvent offentliggör prospekt avseende upptagande till handel av nyemitterade aktier på Nasdaq Stockholm
Capital/Financing Update
2021-03-26 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-23 English
Beslut vid BioInvents extra bolagsstämma den 23 mars 2021
Capital/Financing Update
2021-03-23 Swedish
Resolution at the Extraordinary General Meeting in BioInvent on March 23, 2021
Share Issue/Capital Change
2021-03-23 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-11 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-03-02 English
BioInvent och Transgene har rekryterat den första patienten i en fas I/IIa-studie av det nya onkolytiska viruset BT-001 för behandling av solida tumörer
Regulatory Filings
2021-03-01 Swedish
BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
Regulatory Filings
2021-03-01 English
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2021-02-26 English
Ändring av antalet aktier och röster i BioInvent International AB
Share Issue/Capital Change
2021-02-26 Swedish
Earnings Release 2020
Earnings Release Q4 2020
2021-02-23 Swedish
Earnings Release 2020
Earnings Release Q4 2020
2021-02-23 English
BioInvent International AB brings forward publication of Year-end report 2020
Report Publication Announcement
2021-02-23 English
BioInvent International AB tidigarelägger publicering av bokslutskommuniké 2020
Report Publication Announcement
2021-02-23 Swedish
Notice to Extraordinary General Meeting in BioInvent International AB
Proxy Solicitation & Information Statement
2021-02-23 English
Kallelse till extra bolagsstämma i BioInvent International AB
Proxy Solicitation & Information Statement
2021-02-23 Swedish
BioInvent successfully carries out a directed share issue of approximately SEK 962 million (approximately USD 116 million)
Capital/Financing Update
2021-02-23 English
BioInvent genomför framgångsrikt en riktad nyemission om cirka 962 MSEK (cirka 116 MUSD)
Capital/Financing Update
2021-02-23 Swedish
BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin’s lymphoma patients
Earnings Release FY 2021
2021-01-28 English
BioInvents fas I/IIa-data tyder på att BI-1206 återställer effekten av rituximab hos återfallspatienter med non-Hodgkins lymfom
Earnings Release FY 2021
2021-01-28 Swedish
An van Es Johansson resigns as board director in BioInvent International AB
Board/Management Information
2021-01-18 English
An van Es Johansson avgår som styrelseledamot i BioInvent International AB
Board/Management Information
2021-01-18 Swedish
BioInvent reviderar avtal avseende anti-Fc?RllB-antikroppen BI-1206, före data från fas I/II-studier
Regulatory Filings
2021-01-11 Swedish
BioInvent streamlines agreement on anti-Fc?RllB antibody, BI-1206, ahead of Phase I/II data
Regulatory Filings
2021-01-11 English